Can-Fite BioPharma Ltd. (CANF)
USD 1.36
(-3.55%)
USD 1.36
(-3.55%)
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2023 | - USD | 100.0% |
| 2022 | -39 Thousand USD | 18.75% |
| 2021 | -48 Thousand USD | -104.98% |
| 2020 | 964 Thousand USD | 0.0% |
| 2019 | - USD | 100.0% |
| 2018 | -3.97 Million USD | -20.27% |
| 2017 | -3.3 Million USD | 0.0% |
| 2016 | - USD | 100.0% |
| 2015 | -559.48 Thousand USD | 0.0% |
| 2014 | - USD | 100.0% |
| 2013 | -623.19 Thousand USD | 0.0% |
| 2012 | - USD | -100.0% |
| 2011 | 1.00 USD | 0.0% |
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2024 Q2 | - USD | 0.0% |
| 2024 Q1 | - USD | 0.0% |
| 2023 Q4 | - USD | 0.0% |
| 2023 FY | - USD | 100.0% |
| 2023 Q1 | - USD | 0.0% |
| 2023 Q2 | - USD | 0.0% |
| 2023 Q3 | - USD | 0.0% |
| 2022 Q1 | - USD | 0.0% |
| 2022 Q4 | - USD | 0.0% |
| 2022 Q3 | - USD | 0.0% |
| 2022 FY | -39 Thousand USD | 18.75% |
| 2022 Q2 | - USD | 0.0% |
| 2021 Q1 | -1.01 Million USD | -205.39% |
| 2021 Q4 | - USD | 100.0% |
| 2021 Q3 | -810.99 Thousand USD | 53.52% |
| 2021 Q2 | -1.74 Million USD | -71.75% |
| 2021 FY | -48 Thousand USD | -104.98% |
| 2020 Q1 | - USD | 100.0% |
| 2020 Q2 | -3.56 Million USD | 0.0% |
| 2020 FY | 964 Thousand USD | 0.0% |
| 2020 Q3 | -2.96 Million USD | 16.99% |
| 2020 Q4 | 964 Thousand USD | 132.56% |
| 2019 Q1 | -4.23 Million USD | -214.4% |
| 2019 Q4 | -715 Thousand USD | 86.14% |
| 2019 Q2 | -5.23 Million USD | -23.74% |
| 2019 Q3 | -5.15 Million USD | 1.51% |
| 2019 FY | - USD | 100.0% |
| 2018 FY | -3.97 Million USD | -20.27% |
| 2018 Q4 | 3.7 Million USD | 193.06% |
| 2018 Q3 | -3.97 Million USD | -21.03% |
| 2018 Q2 | -3.28 Million USD | -2.53% |
| 2018 Q1 | -3.2 Million USD | -2307.65% |
| 2017 Q3 | -3.6 Million USD | -7.51% |
| 2017 Q2 | -3.35 Million USD | -38.52% |
| 2017 Q1 | -2.41 Million USD | -6541.04% |
| 2017 FY | -3.3 Million USD | 0.0% |
| 2017 Q4 | 145.17 Thousand USD | 104.03% |
| 2016 FY | - USD | 100.0% |
| 2016 Q2 | -1.71 Million USD | -23.56% |
| 2016 Q4 | -36.42 Thousand USD | 97.92% |
| 2016 Q1 | -1.38 Million USD | -123.15% |
| 2016 Q3 | -1.74 Million USD | -2.12% |
| 2015 Q3 | 1.00 USD | -0.01% |
| 2015 Q2 | 1.00 USD | 100.0% |
| 2015 Q1 | -900.17 Thousand USD | -1198.63% |
| 2015 Q4 | -620.81 Thousand USD | -62087608.74% |
| 2015 FY | -559.48 Thousand USD | 0.0% |
| 2014 Q1 | -845.27 Thousand USD | -35.63% |
| 2014 Q4 | -69.31 Thousand USD | -6931868.2% |
| 2014 Q3 | 1.00 USD | 100.0% |
| 2014 FY | - USD | 100.0% |
| 2014 Q2 | -791.95 Thousand USD | 6.31% |
| 2013 Q2 | -457.65 Thousand USD | 27.22% |
| 2013 Q3 | -457.96 Thousand USD | -0.07% |
| 2013 Q1 | -628.85 Thousand USD | -2510.94% |
| 2013 FY | -623.19 Thousand USD | 0.0% |
| 2013 Q4 | -623.19 Thousand USD | -36.08% |
| 2012 Q1 | - USD | 0.0% |
| 2012 Q3 | - USD | 0.0% |
| 2012 Q4 | -24.08 Thousand USD | -2407964983629.59% |
| 2012 Q2 | - USD | 0.0% |
| 2012 FY | - USD | -100.0% |
| 2011 FY | 1.00 USD | 0.0% |
| 2011 Q4 | - USD | 0.0% |
| 2011 Q3 | - USD | 0.0% |
| Name | Inventory | Inventory Difference |
|---|---|---|
| AIM ImmunoTech Inc. | -1.18 Million USD | 100.0% |
| Ampio Pharmaceuticals, Inc. | 1.00 USD | 100.0% |
| Armata Pharmaceuticals, Inc. | - USD | NaN% |
| Actinium Pharmaceuticals, Inc. | - USD | NaN% |
| Azitra, Inc. | -215.21 Thousand USD | 100.0% |
| Chromocell Therapeutics Corporation | - USD | NaN% |
| Calidi Biotherapeutics, Inc. | - USD | NaN% |
| CEL-SCI Corporation | 2.24 Million USD | 100.0% |
| iBio, Inc. | - USD | NaN% |
| Lineage Cell Therapeutics, Inc. | - USD | NaN% |
| MAIA Biotechnology, Inc. | - USD | NaN% |
| Matinas BioPharma Holdings, Inc. | - USD | NaN% |
| Navidea Biopharmaceuticals, Inc. | 427.34 Thousand USD | 100.0% |
| NovaBay Pharmaceuticals, Inc. | 2.87 Million USD | 100.0% |
| NanoViricides, Inc. | - USD | NaN% |
| Oragenics, Inc. | - USD | NaN% |
| BiomX Inc. | - USD | NaN% |
| BiomX Inc. | - USD | NaN% |
| Protalix BioTherapeutics, Inc. | 19.04 Million USD | 100.0% |
| Palatin Technologies, Inc. | - USD | NaN% |
| Scorpius Holdings, Inc. | 909.15 Thousand USD | 100.0% |
| Theriva Biologics, Inc. | - USD | NaN% |